Abstract
Objectives
Design
Setting and participants
Methods
Results
Conclusions and implications
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the American Medical Directors AssociationReferences
- National Institute for Health and Clinical Excellence: Guidance.in: Dementia: A NICE‒SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care. British Psychological Society The British Psychological Society & The Royal College of Psychiatrists, Leicester (UK)2007
- Prediction of institutionalisation in dementia.Dement Geriatr Cogn Disord. 2008; 26: 65-78
- Dementia time to death: a systematic literature review on survival time and years of life lost in people with dementia.Int Psychogeriatr. 2012; 24: 1034-1045
- The natural history of dementia.Psychogeriatrics. 2014; 14: 196-201
- The natural history of Alzheimer's disease: A brain bank study.J Am Geriatr Soc. 1995; 43: 1248-1255
- A Longitudinal Study of Transitions Between Informal and Formal Care in Alzheimer Disease Using Multistate Models in the European ICTUS Cohort.J Am Med Dir Assoc. 2015; 16 (e1101–e1107): 1104
- The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries—Study design and baseline findings.J Alzheimers Dis. 2013; 36: 385-399
- Survival of people with clinical diagnosis of dementia in primary care: cohort study.BMJ. 2010; 341: c3584
- Risk factors for nursing home placement in Alzheimer's disease: A longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.Gerontologist. 2011; 51: 17-27
- Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: A prospective, observational study of factors affecting survival time from admission to death.BMC Neurol. 2016; 16: 156
- Risk factors that affect life expectancy in Alzheimer's disease: A 15‒year follow‒up.Dement Geriatr Cogn Disord. 2014; 38: 286-299
- Improving access to dementia services for people from minority ethnic groups.Curr Opin Psychiatry. 2013; 26: 409
- The role of cultural factors on clients' attitudes toward caregiving, perceptions of service delivery, and service utilization.Home Health Care Serv Q. 2002; 21: 65-88
- Zorg door de huisarts. Uit: Zorg door de huisarts ‒ Nivel Zorgregistraties eerste lijn: Jaarcijfers 2017 en trendcijfers 2011‒2017. Verantwoording cijfers huisartsenzorg. Uit: NIVEL Zorgregistraties eerste lijn [internet].(2019. Updated 25‒01‒2019)www.nivel.nl/nl/zorgregistraties–eerste–lijn/huisartsenDate accessed: May 13, 2019
- International classification of primary care.Scand J Prim Health Care. 1986; 4: 43-50
- The System of social statistical datasets of Statistics Netherlands: An integral approach to the production of register‒based social statistics.Stat J IAOS. 2014; 30: 411-424
- What is polypharmacy? A systematic review of definitions.BMC Geriatr. 2017; 17: 230
- Multistate models for panel data: The msm package for R.J Stat Software. 2011; 38: 1-29
- ELECT: Estimation of life expectancies using continuous‒time multistate survival models.2014 (Available at: https://cran.r-project.org/web/packages/elect/index.html. Accessed February 10, 2020)
- Multistate models for the analysis of time‒to‒event data.Stat Methods Med Res. 2009; 18: 195-222
- Life expectancy by gender and age for the Dutch population. Central Bureau for Statistics.
- Predictors of survival with Alzheimer's disease: a community‒based study.Psychol Med. 1995; 25: 171-177
- Alzheimer disease and mortality.A 15‒year epidemiological study. 2005; 62: 779-784
- Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia.Acta Neurol Scand. 1995; 91: 159-164
- Survival times in people with dementia: analysis from population based cohort study with 14 year follow‒up.BMJ. 2008; 336: 258‒262
- Health outcomes associated with polypharmacy in community-dwelling older adults: A systematic review.. 2014; 62: 2261-2272
- Polypharmacy in the elderly: A marker of increased risk of mortality in a population‒based prospective study (NEDICES).Gerontology. 2015; 61: 301-309
- Time spent on informal and formal care giving for persons with dementia in Sweden.Health Policy. 2002; 61: 255-268
- Management of the demented elderly patient in the community.Br J Psychiatry. 1978; 132: 441-449
- A longitudinal study of risk factors for community‒based home help services in Alzheimer’s disease: The influence of cholinesterase inhibitor therapy.Clin Intervent Aging. 2013; 8: 329
- Richtlijn diagnostiek en behandeling van dementie.Ned Tijdschr Geneeskd. 2015; 159: A8671
- Family care for immigrants with dementia: The perspectives of female family carers living in The Netherlands.Dementia (London). 2016; 15: 69-84
- Evidence on the relationship between low income and poor health: Is the government doing enough?.Fiscal Stud. 2000; 21: 375-399
- Inequalities in access to medical care by income in developed countries.CMAJ. 2006; 174: 177-183
- Possible sources of bias in primary care electronic health record data use and reuse.J Med Internet Res. 2018; 20: e185
- Improving the quality of EHR recording in primary care: A data quality feedback tool.J Am Med Inform Assoc. 2016; 24: 81-87
Article info
Publication history
Footnotes
This work was supported by the Netherlands Organisation for Health Research and Development (ZonMw) under grant agreement No. 733050403; and the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116020.
Data were collected within the ‘Identifying BESt practices In DEmentia care’ (BESIDE) study, which aimed to identify and characterize best practices in care trajectories of community‒dwelling persons with dementia and their family caregivers. The present study was conducted in collaboration with the Real‒World Outcomes across the Alzheimer's disease spectrum for better care: Multi‒modal data Access Platform (ROADMAP) project, which aimed to identify and use relevant outcomes and data sources across the Alzheimer's disease spectrum to create a disease progression model (38).
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. OJ received through her institution research support from Biogen and the Innovative Medicines Initiatives. SV received research support from ZonMw, Alzheimer Nederland, and the Innovative Medicines Initiatives during the conduct of this study. RH reports the following outside this study: consulting fees from Piramal, Roche and Eisai; grants from Horizon 2020, JPND Joint Programing Neurodegenerative Disease Research, IMI Innovative Medicines Initiative, and national, European and patient charity funding organizations and private‒public collaborations (ZonMw Netherlands; Alzheimer Netherlands; Dutch Flutemetamol Study; Alzheimer Research UK; Swedish National study on Aging and Care; European Brain Council). LV received through her institution research support from Alzheimer Nederland, European Brain Council, and the Innovative Medicines Intiatives. PV reports grants from Innovative Medicine Initiatives and grants from ZonMw during the conduct of the study, nonfinancial support from GE Healthcare, and grants from Biogen, outside the submitted work.
The lead author affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.
The ethics committee of the VU University Medical Center confirmed that the Medical Research Involving Human Subjects Act (WMO) does not apply to the BESIDE study, therefore official approval was not required. Data provided by NIVEL were pseudonymized at each general practice site, and patients were informed about the use of their pseudonymised record data and given the opportunity to object. Data provided by Statistics Netherlands was anonymized. Since these data were recorded for routine administrative purposes no informed consent of the persons included in this database was obtained. The Personal Data Protection Act and the Act on Statistics Netherlands allow for the use of registry data for scientific purposes. This study has been approved according to the governance code of Nivel Primary Care Database, under number NZR‒00315.063.
The BESIDE study has obtained funding from the Netherlands Organisation for Health Research and Development (ZonMw) under grant agreement No. 733050403 (“Identifying best practices in care trajectories of community‒dwelling persons with dementia. A comparison of care trajectories, quality indicators and costs extracted from routine care registrations and health insurance data”). The ROADMAP project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. It is also supported by the Medical Research Council Dementias Platform UK (MR/L023784/1 and MR/009076/1). The researchers confirm independence from funding sources and all authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.
Access to the data sources used in this study can be applied for through the Nivel Primary Care Database and Statistics Netherlands governance bodies.
